טוען...
Targeting Ornithine Decarboxylase for the Prevention of Nonmelanoma Skin Cancer in Humans
Bailey et al. report in this issue of the journal (beginning on page XXX) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral -difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of non-melanoma skin cancer. DFMO is an inhibitor of ornit...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2926793/ https://ncbi.nlm.nih.gov/pubmed/20051367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-09-0248 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|